Tyramine pressor sensitivity in healthy subjects during combined treatment with moclobemide and selegiline

European Journal of Clinical Pharmacology

Volumn 49, Issue 4, 1996, Pages 273-278

  Korn, A ^a   Wagner, B ^a   Moritz, E ^b   Dingemanse, J ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Interaction; Moclobemide; Pharmacodynamics; Selegiline; Tyramine

Indexed keywords

MOCLOBEMIDE; PLACEBO; SELEGILINE; TYRAMINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG POTENTIATION; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; NORMAL HUMAN; PRESSOR RESPONSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; VERTIGO;

EID: 0030066435     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00226327     Document Type: Article

References (34)

1. Blackwell B, Marley E, Price J, Tylor D (1967) Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. Br J Psychiat 113:349-365
2. Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17:1285-1297
3. Houslay MD, Tipton KF, Youdim MBH (1971) Multiple forms of monoamine oxidase, fact and artifact. Life Sci 19:467-478
4. Hasan F, McCrodden JM, Kennedy NP, Tipton KF (1988) The involvement of intestinal monoamine oxidase in the transport and metabolism of tyramine. J Neural Transm [Suppl] 26:1-9
5. Illiet KF, George CF, Davies DS (1980) The effect of monoamine oxidase inhibitors on first-pass metabolism of tyramine in dog intestine. Biochem Pharmacol 29:2551-2556
6. Dollery CT, Brown MJ, Davies DS, Lewis PJ, Strolin-Benedetti M (1983) Oral absorption and concentration-effect relationship of tyramine with and without cimoxatone, a type-A specific inhibitor of monoamine oxidase. Clin Pharmacol Ther 34:651-662
7. Da Prada M, Kettler R, Keller HH, Burkard WP, Muggli-Manigilio D, Haefely WE (1988) Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J Pharmacol Exp Ther 248:400-414
8. Haefely W, Burkard WP, Cesura AM, Kettler R, Lorez HP, Martin JR, Richards JG, Scherschlicht R, Da Prada M (1992) Biochemistry and pharmacology of moclobemide, a prototype RIMA. Psychopharmacology [Suppl] 106:6-14
9. Fitton A, Faulds D, Goa KL (1992) Moclobemide: A review of its pharmacological properties and therapeutic use in depressive illness. Drugs 43:561-596
10. Priest RG, Schmid-Burgk W (1994) Moclobemide in the treatment of depression. Rev Contemp Pharmacother 5:35-43
11. Kom A, Da Prada M, Raffesberg W, Gasic S, Eichler HG (1988) Effect of moclobemide, a new reversible monoamine oxidase inhibitor, on absorption and pressor effect of tyramine. J Cardiovasc Pharmacol 11:17-23
12. Kom A, Da Prada M, Raffesberg W, Allen S, Gasic S (1988) Tyramine pressor effect in man: studies with moclobemide, a novel, reversible monoamine oxidase inhibitor. J Neural Transm [Suppl] 26:57-71
13. Wijnands S, Chang PC, Blauw GJ, van den Krogt J, Gieschke R, Schoerlin M-P, van Brummelen P (1989) Potentiation of the pressor effect of oral and intravenous tyramine during administration of the selective MAO-A inhibitor moclobemide in healthy volunteers. J Psychopharmacol 3:36-44
14. Chrisp P, Mammen GJ, Sorkin ME (1991) Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease. Drugs Aging 1:228-248
15. Youdim MBH, Da Prada M, Amrein R (1988) The cheese effect and new reversible MAO-A inhibitors. J Neural Transm [Suppl] 26:1-136
16. Waldmeier PC, Felner AE (1978) Deprenyl: loss of selectivity for inhibition of B-type MAO after repeated treatment. Biochem Pharmacol 27:801-802
17. Cummings JL (1992) Depression and Parkinson's disease. Am J Psychiat 149:443-454
18. Thornton C, Dore CJ, Elsworth JD, Herbert M, Stern GM (1980) The effect of deprenyl, a selective monoamine oxidase B inhibitor, on sleep and mood in man. Psychopharmacology 70:163-166
19. Bieck PR, Antonin K-H (1988) Oral tyramine pressor test and the safety of monoamine oxidase inhibitor drugs: comparison of brofaromine and tranylcypromine in healthy subjects. J Clin Psychopharmacol 8:237-245
20. Guentert TW, Mayerson M (1994) Clinical-pharmacokinetic profile of moclobemide and its comparison with other MAO-inhibitors. Rev Contemp Pharmacother 5:19-34
21. Bieck PR, Antonin KH, Schmidt E (1993) Clinical pharmacology of reversible monoamine oxidase-A inhibitors. Clin Neuropharmacol 16 [Suppl 2]:S34-S41
22. Felner AE, Waldmeier PC (1979) Cumulative effects of irreversible MAO inhibitors in vivo. Biochem Pharmacol 28:995-1002
23. Heinonen EH, Lammintausta R (1991) A review of the pharmacology of selegiline. Acta Neurol Scand 84 [Suppl 136]: 44-59
24. Gerlach M, Riederer P, Youdim M (1992) The molecular pharmacology of L-deprenyl. Eur J Pharmacol 226:97-108
25. Sunderland T, Mueller EA, Cohen RM, Jimerson DC, Pickar D, Murphy DL (1985) Tyramine pressor sensitivity changes during deprenyl treatment. Psychopharmacology 86: 432-437
26. Schulz R, Antonin K-H, Hoffmann E, Jedrychowski M, Nilsson E, Schick C, Bieck PR (1989) Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline. Clin Pharmacol Ther 46:528-536
27. Neff NH, Yang HYT (1974) Another look of monoamine oxidases and the monoamine oxidase inhibitor drugs. Life Sci 14:2061-2074
28. Heinonen EH, Anttila MI, Lammintausta RAS (1994) Pharmacokinetic aspects of I-deprenyl (selegiline) and its metabolites. Clin Pharmacol Ther 56:742-749
29. Dingemanse J, Kneer J, Wallnöfer A, Kettler R, Zürcher G, Koulu M, Kom A (1995) Pharmacokinetic-pharmacodynamic interactions between two selective monoamine oxidase inhibitors: moclobemide and selegiline. Clin Neuropharmacol (in press)
30. Koulu M, Scheinin M, Kaarttinen A, Kallio J, Pyykkö K, Vuorinen J, Zimmer RH (1989) Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers. Br J Clin Pharmacol 27:243-255
31. Youdim MBH, Finberg JPM (1986) MAO type B inhibitors as adjunct to L-Dopa therapy. Adv Neurol 45:127-136
32. Lader MH, Sakalis G, Tansella M (1970) Interactions between sympathomimetic amines and a new monoamine oxidase inhibitor. Psychopharmacology 18:118-123
33. Reynolds GP, Elsworth JD, Blau K, Sandler M, Lees AJ, Stern GM (1978) Deprenyl is metabolised to metamphetamine and amphetamine in man. Br J Clin Pharmacol 6:542-544
34. Somerset Pharmaceuticals Inc. (1995) Package insert Eldepryl®